SPS 2008 Sponsors

Diamond
($15,000+)

Emerald
($10,000 to $14,999)

Ruby
($6,000 to $9,999)

Opal
($3,000 to $5,999)

Sapphire
(Up to $2,999)

Lewis B. Kinter & Terry Timberlake-Kinter

Sponsored Presentations

Study design Safety Pharmacology: Emerging Trends in Drug Development
Tuesday, September 23, 2008
7:00 AM–8:00 AM

Session Chair, Simon Authier, LAB Research

Speakers:
Dennis Murphy, GlaxoSmithKline Pharmaceuticals

The added value of measuring cardiovascular and respiratory functions simultaneously in safety pharmacology: Identifying cardiopulmonary dependencies.

Current and future methods of conducting CV and respiratory studies in safety pharmacology will be presented followed by a discussion of cardiopulmonary function dependencies and examples of how respiratory changes can affect CV parameters and how CV changes can affect respiratory parameters.

Michael Pugsley, Johnson & Johnson

Safety Pharmacology Investigations in Toxicology Studies: Added value or limitation?

Emerging technologies have fueled a trend to add Safety Pharmacology endpoints into toxicology studies. The usefulness and limitations of this approach will be discussed.

Jean-Pierre Valentin, AstraZeneca

The predictive value of safety pharmacology assays to the clinical outcome

Selection of the most appropriate models is critical in drug development. The stakes are high with impacts on resource allocation, timing and sequence of safety screening assays.

For more information about how to host an Sponsor Presentation during the SPS Annual Meeting, please complete the Sponsor Presentation form and send it to SPS Headquarters.

The use and application of non-invasive multi-parametric telemetry in cardiovascular research: comparison against an implantable system, and evaluation of integrated semi-invasive VAP-derived blood pressure measurements.

Tuesday, September 23, 2008
12:00 Noon–1:00 PM

Carlos Del Rio, PhD, of Qtest Labs, will present a set of studies he conducted to formally compare the signal characteristics of single-lead electrocardiograms simultaneously collected in beagle dogs using non-invasive and invasive telemetry techniques, and a hard-wire setup. In particular, the properties, response, and performance of a wearable (non-invasive) telemetry system (emkaPACK; emka TECHNOLOGIES) will be evaluated side-by-side against a standard implantable system. These comparisons will be performed using a common data acquisition/analysis system under a variety of physiological conditions commonly encountered/required in cardiovascular research and/or pre-clinical testing (pharmacological challenge, exercise test, anesthesia, etc.).In addition, the performance and response characteristics of minimally invasive, vascular access port-derived telemetered pressure signals will be evaluated.

An ITS Forum on Telemetry:
Applications and Benefits of ITS

Wednesday, September 24, 2008
12:00 Noon–1:30 PM
Monona Terrace Convention Center
Hall of Ideas, Room G

Come hear three different speakers from three different companies on how they use ITS to enhance their research

1. Quick study turnaround. VR2 Data reduction and reporting proven to increase accuracy and drastically decrease study turnaround time. Make sure your safety pharmacology telemetry study data is available within 2 weeks upon completion of the inlife telemetry data acquisition.
2. The smallest implant available for primates – the T31. Monitor respiration, ECG and temperature in a 2.5 kg primate for periods exceeding 120 days with multiple frequencies and minimal signal distortion and dropout.
3. Noninvasive telemetry with the ITS PhysioJacket. One scientist evaluates our PhysioJacket system against an implant. The results will surprise you!

Elsevier

Wednesday, September 24, 2008
12:00 Noon–2:00 PM
Monona Terrace Convention Center
Meeting Rooms O & P

Safety pharmacology research requires convenient access to numerous data sources.
This process can be very time consuming and frustrating.

• How do you currently find drugs that are showing cardiovascular toxicities or abnormal ECG?
• Are you spending too much time comparing toxicity profiles between human and animal models?
• How easy is it for you to find QT prolongation issue for a particular drug class?
• Do you need to access more high value preclinical and clinical drug safety information?

Many researchers are familiar with the value of FDA approval packages and EMEA approval documents. PharmaPendium compiles several high value drug safety data sources for approved drugs, including these two data sources. With manual data extraction, integration, indexing, and text searching capability, etc., it enables easy access to these vital data sources. It also creates new ways for toxicity and adverse effect comparison and analysis.

A Unique Educational (and Entertaining) Program Featuring DSI’s very first scientific…

DATA BLITZ !

New Applications of Telemetric and Physiological Monitoring in Pharmacology and Safety Pharmacology

Wednesday, September 24, 2008
5:30 PM–7:30 PM
Monona Terrace Community
Terrace Room

Live presentations will include brief overviews of the latest safety pharmacology applications using wired and wireless telemetry with automated analysis to monitor and analyze physiological data. Twenty short scientific presentations will focus on the most recent applications and new method advances in Cardiovascular, CNS, and Respiratory safety pharmacology data assessment. This is a unique opportunity to meet and talk with your peers about their most recent research in a relaxed and informal setting.

Lite hors d’oeuvres and beverages served. HH